Irbesartan Macleods Pharma Uk (Irbesartan)

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. This results in relaxed blood vessels, reduced fluid retention, and lower systemic blood pressure.

The appropriate dose of Irbesartan is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments are made according to clinical judgment.

Irbesartan is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy. Limited data are available for breastfeeding; therefore, use is generally discouraged unless the benefit outweighs the potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the angiotensin II receptor blocker (ARB) class, offering similar blood‑pressure‑lowering efficacy to ACE inhibitors but with a lower incidence of cough. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than directly on vascular smooth muscle.

Store the product at room temperature, below 25 °C, in the original packaging. Keep it away from moisture and direct sunlight to maintain stability.

Irbesartan is taken orally, usually as a tablet, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether the dose should be taken once daily or divided.

Serious adverse events include angioedema, hyperkalaemia, and acute renal failure. Patients should be educated to seek immediate medical attention if they experience swelling of the face, lips, tongue, or difficulty breathing, as well as signs of severe kidney dysfunction.

Irbesartan is contraindicated in patients with known hypersensitivity to the drug or any ARB, in pregnant women, and in individuals with severe hepatic impairment. Caution is also advised for patients with bilateral renal artery stenosis.